On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

Johnson & Johnson (J&J ... In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder (who were ...

CEO/Founder Nicole Tinson and Senior Vice President of Programs and Partnership Dr. Dennis Johnson, who is a native of Chicago's South Side, joined Jewell Hillery via Zoom on Sunday's WGN Weekend ...

Payment options are available based on insurance coverage. The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in children aged 4 ...

The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic reactions in patients who weigh between 15 and 30 kilograms, the company said on ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

Milestone Pharmaceuticals Inc. announced that the FDA has ... for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal Supraventricular Tachycardia (PSVT). If approved, Milestone ...

FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Join Nic Chahine ...